PT-141 / Bremelanotide

Bremelanotide, also known as PT-141, is a synthetic cyclic heptapeptide marketed as Vyleesi. It is an FDA-approved medication for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Its mechanism involves acting as a melanocortin receptor agonist.

What is PT-141 / Bremelanotide?

Bremelanotide, or PT-141, is a synthetic cyclic heptapeptide that functions as a melanocortin receptor agonist. Unlike naturally occurring human peptides, it was developed from an alpha-melanocyte-stimulating hormone scaffold. It is not an endogenous human peptide. Bremelanotide is specifically formulated as an injection and is marketed in the US under the brand name Vyleesi.

Approved Indications and Dosage

Bremelanotide is FDA-approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval is based on strong evidence for its efficacy in this specific population and condition. The recommended FDA-labeled dose is 1.75 mg, administered subcutaneously, as needed, at least 45 minutes before anticipated sexual activity. Patients should not exceed one dose within 24 hours or eight doses per month. If no improvement is observed after 8 weeks of treatment, discontinuation is advised.

Compounding and Regulatory Status

Bremelanotide is a component of an FDA-approved drug product, which places it in a distinct category compared to speculative gray-market peptides. However, its status as an approved drug means that any 503A compounding analysis must carefully consider "essentially a copy" restrictions and other statutory conditions. While some compounders have produced bremelanotide (PT-141), this does not automatically confer compliant 503A status for such compounded products. The FDA maintains a close watch on compounding practices, as evidenced by actions taken against companies promoting compounded versions of approved medications.

Current Status

Bremelanotide (Vyleesi) holds a clear position as an FDA-approved therapeutic option for HSDD in premenopausal women. Its regulatory pathway and approved indication make it distinct from many other peptides that lack such rigorous validation. While it is a recognized product, its use requires careful attention to its specific indication, potential cardiovascular warnings, and the strict 503A copy restrictions for compounding pharmacies.